



Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX ANNOUNCEMENT

Telix Results of Annual General Meeting

Sydney (Australia) – 22 May 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to advise that each of the resolutions put to today's Annual General Meeting of shareholders (AGM) was carried, decided by way of a poll.

The outcomes in respect of each resolution on the agenda at today's AGM are set out in the attached report, in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

Authorised for lodgement by:

A handwritten signature in dark ink, appearing to read 'Genevieve Ryan'.

Genevieve Ryan
Company Secretary

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Telix's lead imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also known as ⁶⁸Ga PSMA-11 and marketed under the brand name Ilucix®), has been approved by the U.S. Food and Drug Administration (FDA)¹, by the Australian Therapeutic Goods Administration (TGA)², and by Health Canada³. No other Telix product has received a marketing authorisation in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [X](#) and [LinkedIn](#).

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

¹ Telix ASX disclosure 20 December 2021.

² Telix ASX disclosure 2 November 2021.

³ Telix ASX disclosure 14 October 2022.

Legal Notices

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification.

This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.

©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.



TELIX PHARMACEUTICALS LIMITED

RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

ANNUAL GENERAL MEETING
Wednesday, 22 May, 2024

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

| Resolution Voted on at the meeting | | | Proxy Votes (as at proxy close) | | | | Direct vote (as at proxy close): | | Total votes cast in the poll (where applicable) | | | Result |
|------------------------------------|---|---------------|---------------------------------|--------------------|----------------------------|-----------|----------------------------------|--------------------|---|--------------------|------------|---------|
| No | Short Description | Strike Y/N/NA | For | Against | Discretionary (open votes) | Abstain | For | Against | For | Against | Abstain ** | |
| 1 | ADOPT THE 2023 REMUNERATION REPORT | N | 101,844,546 88.09% | 6,507,418 5.63% | 2,085,379 1.80% | 1,018,516 | 5,039,360 4.36% | 143,985 0.12% | 111,096,827 94.35% | 6,654,203 5.65% | 1,020,516 | Carried |
| 2 | RE-ELECT DR ANDREAS KLUGE AS DIRECTOR | NA | 107,782,032 74.41% | 2,669,780 1.84% | 2,085,379 1.44% | 97,374 | 32,267,318 22.28% | 34,724 0.02% | 166,948,571 98.41% | 2,704,504 1.59% | 97,374 | Carried |
| 3 | APPROVE THE AMENDED EQUITY INCENTIVE PLAN AND THE GRANT OF EQUITY SECURITIES UNDER THE EQUITY INCENTIVE PLAN | NA | 100,606,252 86.40% | 8,549,904 7.34% | 2,092,379 1.80% | 202,470 | 4,871,430 4.18% | 316,869 0.27% | 109,694,753 92.52% | 8,871,573 7.48% | 205,320 | Carried |
| 4 | APPROVE THE GRANT OF PERFORMANCE SHARE APPRECIATION RIGHTS TO THE MANAGING DIRECTOR AND GROUP CHIEF EXECUTIVE OFFICER | NA | 104,429,745 89.60% | 4,816,774 4.13% | 2,141,606 1.84% | 86,245 | 4,024,046 3.45% | 1,140,804 0.98% | 112,720,089 94.98% | 5,962,378 5.02% | 89,095 | Carried |
| 5 | APPROVE AN INCREASE IN THE MAXIMUM AGGREGATE REMUNERATION OF THE NON-EXECUTIVE DIRECTORS | NA | 109,012,614 93.62% | 89,829 0.08% | 2,141,606 1.84% | 197,384 | 4,542,448 3.90% | 653,319 0.56% | 117,788,360 99.37% | 745,948 0.63% | 235,234 | Carried |

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item